877 / 1851
The addition of Bevacizumab to TMZ-radiotherapy did not improve OS.
Improved PFS and KPS were observed with Bevacizumab
Rate of adverse events was higher with Bevacizumab (G3 related: 32% vs 15%)
Alternative drugs: Bevacizumab (AVAglio)
Chinot OL. et al. NEJM 2014;370
921 GBM
patients
R
Concurrent
TMZ/RT
Adjuvant TMZ
Weeks
10 14 18 22 26 30
RT Alone
R
6
Temozolomide
75 mg/m
2
po qd for 6 weeks,
then 150–200 mg/m
2
po qd d1–5 every 28 days for 6 cycles
Focal RT
daily — 30 x 2 Gy
Total dose 60 Gy
0
Concurrent
TMZ/RT
Adjuvant TMZ
Weeks
10 14 18 22 26 30
RT Alone
R
6
Temozolomide
75 mg/m
2
po qd for 6 weeks,
then 150–200 mg/m
2
po qd d1–5 every 28 days for 6 cycles
Focal RT
daily — 30 x 2 Gy
Total dose 60 Gy
0
+ Bevacizumab
A) CONTROL ARM
B) EXPERIMENTAL ARM
Median OS
16.8 vs 16.7 months
Median PFS
10.6 vs 6.2 months